Financière de Tubize SAの浮動株式数
Financière de Tubize SAの浮動株式数は何ですか。
Financière de Tubize SAの浮動株式数は19.180M 43.12%です。
浮動株式数の定義は何ですか。
浮動株式数は、ロックインされた株式とは対照的に、公的投資家の手にある企業の株式の一部です。
Shares float represents the portion of shares of a corporation that are in the hands of public investors as opposed to locked-in stock held by promoters, company officers, controlling-interest investors, or government. This number is sometimes seen as a better way of calculating market capitalization because it provides a more accurate reflection of what public investors consider the company to be worth. In this context, the float may refer to all the shares outstanding that can be publicly traded
The float is calculated by subtracting the locked-in shares from outstanding shares. Stocks with smaller floats tend to be more volatile than those with larger floats. In general, the large holdings of founding shareholders, corporate cross-holdings, and government holdings in partially privatized companies are excluded when calculating the size of a public float.
EURONEXTのセクタHealth Careにおける浮動株式数の企業と比べるFinancière de Tubize SA
Financière de Tubize SAは何をしますか。
Financière de Tubize S.A., through its interest in UCB, operates as a biopharmaceutical company worldwide. It discovers and develops medicines and solutions in the therapeutic areas of neurology and immunology diseases. The company's principal products include Cimzia for treating ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Briviact, Vimpat, and Keppra for the treatment of epilepsy partial-onset seizures; Nayzilam, a nasal spray; and Neupro for treating Parkinson's disease and restless legs syndrome. It also offers Zyrtec and Xyzal for the treatment of allergy; Nootropil for the treatment of psycho-organic syndromes or cognitive decline and cortical myoclonus; and Xyrem for use in treating narcolepsy with cataplexy in adult patients. The company's products in pipeline include padsevonil for drug resistant epilepsy; UCB0107 for treating progressive supranuclear palsy; UCB0599 for Parkinson's disease; UCB7858 for auto-inflammatory diseases; bimekizumab to treat psoriasis, psoriatic arthritis, hidradenitis suppurativa, and axial spondyloarthritis; rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; and dapirolizumab pegol for systemic lupus erythematosus. Financière de Tubize S.A. is based in Brussels, Belgium.
Financière de Tubize SAと類似の浮動株式数
- Cogeco Communicationsの浮動株式数は19.147M 61.46%です。
- Celebrity Fashionsの浮動株式数は19.151M 40.09%です。
- Polaris Infrastructureの浮動株式数は19.161M 98.63%です。
- Jackson Acquisitionの浮動株式数は19.170M 86.16%です。
- IOL Chemicals and Pharmaceuticalsの浮動株式数は19.176M 32.67%です。
- Atacama Copperの浮動株式数は19.177M 55.79%です。
- Financière de Tubize SAの浮動株式数は19.180M 43.12%です。
- Rice Acquisitionの浮動株式数は19.194M 80.89%です。
- Voltの浮動株式数は19.195M 69.88%です。
- New Providence Acquisitionの浮動株式数は19.208Mです。
- CRISILの浮動株式数は19.209M 26.49%です。
- Select Interior Conceptsの浮動株式数は19.209M 75.22%です。
- Bonheur ASAの浮動株式数は19.218M 45.18%です。